TORONTO — Trillium Therapeutics Inc. has signed a deal to be bought by Pfizer Inc. in an agreement valued at US$2.26 billion. Under the plan, Pfizer will pay US$18.50 per share in cash for the Mississauga, Ont.--based biotechnology company..
Read more >